The manufacturers behind the obesity drugs Mounjaro and Zepbound report that sales are doubling this year, reflecting continued strong demand for medications in the obesity market. According to the company, the growth in these products is also accelerating its overall sales performance. The reports from multiple outlets describe the same core message from the maker: Mounjaro and Zepbound are driving the rise in revenue and are contributing to a faster pace of overall sales than previously seen. While the outlets share the same framing, they do not provide additional detailed figures beyond the assertion that Mounjaro sales double during the year. The coverage is limited to the manufacturer’s statements and focuses on the broader “obesity drug boom” rather than on independent confirmation, regulatory developments, or comparative performance against competitors. The articles also do not specify whether the doubling refers to a specific region, time period within the year, or particular dosage formulations.